Physician profile
Scott Herbert
NPI 1548340870
$14,129.48
in general payments reported to CMS, 2019-2025
71 companies · $3,809 in 2025
The $3,809 reported for 2025 was more than what 78% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $294 · 2021: $839 · 2022: $841 · 2023: $3,781 · 2024: $4,208 · 2025: $3,809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,346.14 |
| Education | $452.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,327.50 | 2020-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,100.61 | 2020-2025 | Enhertu, Imfinzi, Tagrisso |
| E.R. Squibb & Sons, L.L.C. | $845.80 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Janssen Biotech, INC. | $834.87 | 2019-2025 | Rybrevant, Carvykti, Erleada |
| Incyte Corporation | $713.16 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Gilead Sciences, INC. | $608.46 | 2019-2025 | Trodelvy |
| Exelixis INC. | $560.52 | 2019-2025 | Cabometyx |
| Celgene Corporation | $510.71 | 2022-2025 | Reblozyl, Opdualag |
| Pfizer INC. | $507.35 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $497.73 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Seagen INC. | $489.70 | 2019-2023 | Padcev, Adcetris, Tukysa |
| Genentech USA, INC. | $445.99 | 2019-2025 | Rozlytrek, Alecensa, Polivy |
| Genzyme Corporation | $379.29 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $376.27 | 2022-2025 | Alunbrig, Fruzaqla, Iclusig |
| Kite Pharma, INC. | $351.92 | 2021-2025 | Yescarta |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $325.13 | 2023-2025 | |
| Abbvie INC. | $256.21 | 2022-2025 | |
| Emd Serono, INC. | $255.26 | 2023-2025 | Bavencio, Tepmetko |
| Daiichi Sankyo INC. | $209.67 | 2023-2025 | Enhertu, Injectafer |
| Array Biopharma INC | $208.70 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Regeneron Healthcare Solutions, INC. | $202.48 | 2023-2025 | Libtayo |
| Blueprint Medicines Corporation | $201.14 | 2023-2025 | Ayvakit |
| Servier Pharmaceuticals LLC | $193.47 | 2022-2025 | |
| Beigene USA, INC. | $192.41 | 2021-2025 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $192.14 | 2021-2025 | |
| Karyopharm Therapeutics INC. | $145.03 | 2023-2025 | Xpovio |
| Tersera Therapeutics LLC | $140.22 | 2023-2025 | Zoladex |
| Lilly USA, LLC | $131.39 | 2021-2024 | Jaypirca, Retevmo, Verzenio |
| Zimmer Biomet Holdings, INC. | $111.16 | 2023 | Persona |
| Astellas Pharma US INC | $103.71 | 2023-2025 | Xtandi |
| Glaxosmithkline, LLC. | $95.97 | 2021-2025 | Ojjaara |
| Amgen INC. | $90.77 | 2019-2023 | Xgeva, Vectibix, Nplate |
| Sobi, INC | $89.78 | 2024-2025 | |
| Stemline Therapeutics INC. | $79.72 | 2023-2024 | Orserdu |
| Pharmaessentia USA Corporation | $79.51 | 2023-2024 | Besremi |
| Puma Biotechnology, INC. | $71.51 | 2020-2023 | |
| Springworks Therapeutics, INC. | $71.32 | 2024-2025 | Ogsiveo |
| Rigel Pharmaceuticals, INC. | $68.80 | 2020-2025 | Rezlidhia, Tavalisse, Gavreto |
| Genmab U.S., INC. | $67.74 | 2024 | Epkinly |
| Ipsen Biopharmaceuticals, INC | $67.06 | 2024-2025 | Onivyde |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.43 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $61.10 | 2021-2023 | Imbruvica |
| Taiho Oncology, INC. | $60.73 | 2021-2024 | |
| Jazz Pharmaceuticals INC. | $54.77 | 2021-2025 | |
| Legend Biotech USA INC. | $49.46 | 2025 | Carvykti |
| Deciphera Pharmaceuticals INC. | $38.64 | 2025 | Qinlock, Romvimza |
| Alexion Pharmaceuticals, INC. | $37.51 | 2023 | Ultomiris |
| Mirati Therapeutics, INC. | $35.97 | 2024 | Krazati |
| Kyowa Kirin, INC. | $32.73 | 2021-2023 | Poteligeo |
| Spectrum Pharmaceuticals INC. | $31.80 | 2024-2025 | Rolvedon |
| US Oncology Corporate, INC. | $31.64 | 2024 | |
| Adaptive Biotechnologies Corporation | $30.76 | 2022-2025 | Clonoseq |
| Roche Diagnostics Corporation | $30.25 | 2019 | |
| Geron Corporation | $29.36 | 2025 | Rytelo |
| Foundation Medicine, INC. | $27.05 | 2023 | Foundationone Liquid Cdx |
| Menarini Silicon Biosystems, INC. | $24.72 | 2025 | |
| Eusa Pharma (US) LLC | $24.67 | 2021 | |
| Acrotech Biopharma INC. | $22.69 | 2024 | Beleodaq |
| Agios Pharmaceuticals, INC. | $22.00 | 2025 | |
| Cycle Pharmaceuticals INC | $21.59 | 2025 | Phyrago |
| Nuvation Bio INC. | $21.40 | 2025 | Ibtrozi |
| Tempus Ai, INC | $20.63 | 2024 | |
| Dova Pharmaceuticals | $19.46 | 2019 | |
| Beone Medicines USA, INC. | $19.38 | 2025 | Tevimbra |
| Cti Biopharma Corp. | $19.17 | 2023 | Vonjo |
| Tactile Systems Technology INC | $19.00 | 2025 | Flexitouch Plus, Nimbl |
| Aveo Pharmaceuticals, INC. | $17.50 | 2023 | Fotivda |
| Apellis Pharmaceuticals, INC. | $16.22 | 2025 | |
| Celltrion USA INC. | $15.44 | 2024 | Vegzelma |
| Caris Mpi, INC. | $14.52 | 2025 | Mi Cancer Seek |
| Fresenius Kabi USA, LLC | $13.71 | 2024 | Stimufend |
Drugs and devices associated with these payments
Enhertu $529Pluvicto $502Reblozyl $447Kisqali $419Keytruda $394Trodelvy $339Lenvima $325Cabometyx $317Rybrevant $286Venclexta $277Opdivo $269Imfinzi $267Yescarta $262Xtandi $261Carvykti $241Jakafi $241Opdualag $219Braftovi $209Lutathera $205Libtayo $202Ayvakit $201Mektovi $193Tukysa $182Adcetris $182Brukinsa $164Sarclisa $161Xpovio $145Zoladex $140Scemblix $136Elrexfio $135Alunbrig $129Talzenna $127Lorbrena $125Alecensa $124Rozlytrek $124Polivy $123Erleada $115Krazati $114Persona $111Padcev $107Xalkori $106Bosulif $105Lunsumio $102Gavreto $99.34Monjuvi $96.60Welireg $96.04Ibrance $95.73Talvey $94.66Darzalex $93.42Vitrakvi $92.56Stivarga $92.56Jaypirca $86.89Tibsovo $86.41Imbruvica $85.73Nubeqa $85.07Ojjaara $81.49Orserdu $79.72Tecvayli $79.62Besremi $79.51Phesgo $76.40Fruzaqla $73.59Retevmo $73.31Tagrisso $71.96Ogsiveo $71.32Inlyta $71.31Voranigo $68.73Perjeta $68.25Epkinly $67.74Onivyde $67.06Lynparza $66.93Orgovyx $65.40Columvi $64.60Tecentriq $62.38Verzenio $59.78Fabhalta $59.08Doptelet $57.19Akeega $52.36Balversa $52.36Tasigna $52.19Vonjo $51.76Rezlidhia $49.47Tavalisse $49.47Besponsa $44.25Bavencio $43.75Zynyz $41.83Iclusig $40.61Xofigo $39.41Qinlock $38.64Romvimza $38.64Ultomiris $37.51Pemazyre $37.26Inqovi $35.16Lonsurf $35.16Kadcyla $35.00Paxlovid $33.77Itovebi $32.70Rolvedon $31.80Rytelo $29.36Jevtana $28.18Emrelis $28.05
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Herbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.